uniQure (NASDAQ:QURE) Insider Kylie O’keefe Sells 15,936 Shares

uniQure N.V. (NASDAQ:QURE) insider Kylie O’keefe sold 15,936 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $431,228.16. Following the sale, the insider owned 108,864 shares in the company, valued at approximately $2,945,859.84. The trade was a 12.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

uniQure Trading Up 2.8%

NASDAQ QURE traded up $0.75 on Friday, hitting $27.57. 835,627 shares of the company were exchanged, compared to its average volume of 2,601,234. The company’s 50 day moving average price is $22.31 and its 200-day moving average price is $21.76. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm has a market capitalization of $1.74 billion, a P/E ratio of -7.92 and a beta of 0.98. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.03. The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Analysts predict that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

QURE has been the subject of a number of research analyst reports. Stifel Nicolaus set a $28.00 price target on shares of uniQure in a research report on Tuesday, May 5th. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Royal Bank Of Canada upgraded shares of uniQure from a “sector perform” rating to an “outperform” rating and increased their target price for the stock from $11.00 to $35.00 in a research report on Monday, March 9th. HC Wainwright decreased their target price on shares of uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Finally, TD Cowen restated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, uniQure has an average rating of “Moderate Buy” and a consensus price target of $42.83.

Institutional Investors Weigh In On uniQure

Several large investors have recently made changes to their positions in the company. Jones Financial Companies Lllp grew its stake in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of uniQure by 5.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 533 shares in the last quarter. Arizona State Retirement System grew its stake in shares of uniQure by 6.0% in the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after buying an additional 627 shares in the last quarter. Ensign Peak Advisors Inc grew its stake in shares of uniQure by 21.7% in the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after buying an additional 650 shares in the last quarter. Finally, FNY Investment Advisers LLC grew its stake in shares of uniQure by 76.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 718 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.